CLINICAL TRIAL article
Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1577468
This article is part of the Research TopicCombination Therapies in Cancer Treatment: Enhancing Efficacy and Reducing ResistanceView all 14 articles
Clinical Outcomes of DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) Combinations in Cancer: A Data-Driven Review
Provisionally accepted
- 1Lantern Pharma, Dallas, TX, United States
- 2Starlight Therapeutics, Plano, TX, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The combination of DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) has been extensively studied to improve therapeutic outcomes. While both groups of agents show promise individually, DDAs are limited by tumor resistance, and DDRis are limited by specific genetic context (1)(2). Combining DDAs with DDRis may overcome these challenges and enhance patient outcomes. This review systematically analyzes clinical trials investigating the combination of DDAs and DDRis by dividing them into two sections: PARP and non-PARP inhibitors. An evaluation was conducted on 221 DDA-DDRi combination-arm trials involving 22 DDAs and 46 DDRis. DDAs were classified into eight subclasses, and DDRis into 14 distinct subclasses based on their mechanisms of action and specific targets, respectively. 89 of the 221 combination-arm trials had interpretable outcomes and were selected for further analysis. These were assigned outcome scores based on predefined criteria, reflecting their clinical effectiveness, safety, and benefit across different tumor types and patient populations. Our analysis emphasizes the patterns in treatment effectiveness, safety, and emerging trends across various cancer types and discusses the potential of biomarkers to guide treatment selection and improve patient outcomes. This review outlines an understanding of the recent state of DDA-DDRi combinations, offering critical insights for refining future cancer treatment strategies.
Keywords: DNA-damaging agents, DNA damage response inhibitors, PARP inhibitors, combination therapy, clinical trials, DNA repair pathways, cancer treatment, biomarkers
Received: 15 Feb 2025; Accepted: 12 May 2025.
Copyright: © 2025 Fontenot, Biyani, Bhatia, Ewesuedo, Chamberlain and Sharma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Rick Fontenot, Lantern Pharma, Dallas, TX, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.